Tuesday, July 22, 2014
Inquirer Daily News

Archive: June, 2013

Fleet Enema label misleads – it’s not just “saline”

Friday, June 28, 2013, 6:00 AM
In 2006 the FDA warned consumers about kidney failure seen in some users of oral sodium phosphates (OSP) like Fleet’s Phospho-soda. FDA’s review of adverse event data did not show kidney problems when these over-the-counter oral products were used at lower doses for laxative use. But they... Read more

Nice bonds for conservative investors

Thursday, June 27, 2013, 10:12 AM
A monthly review of Big Cap pharma stocks by Sanford Bernstein, a large fee-analyst company, offers some insights in what it says and what it doesn't say. As with other equity analysts, Bernstein draws a wide distinction between a company's/sector's fundamentals and its value as a stock. Based on... Read more

Patient friendly service or danger up ahead?

Thursday, June 20, 2013, 6:00 AM
Doctors sometimes provide patients with drug samples to get them started on a needed medication in a timely manner. Hospital emergency departments (EDs) have also sent patients home with starter doses or unit dose packages from the hospital pharmacy. This allows the patient to start taking the medicine... Read more

The reactionary myth that's letting finance managers ruin pharma companies

Wednesday, June 19, 2013, 6:00 AM
Pharma's finance managers have come in for some heavy hits in this space during the past two years. They deserve every swat and then some. CFOs and their henchmen have destroyed Big Pharmas foundation as research-driven, growth companies and have driven off some of its most experienced, capable people... Read more

Avoid look-alike medication mistakes

Friday, June 14, 2013, 6:00 AM
We often receive reports from people who took the wrong medicine or the wrong dose because of mix-ups with products that looked similar. Sometimes people rely on the appearance of tablets, capsules, or packages to identify their medicines, instead of reading the labels carefully. Look at these eye... Read more

Pharma as a fading power hitter

Wednesday, June 12, 2013, 6:00 AM
Approximately half the drugs now in clinical development involve an approach known as targeted therapy. Last week's posting discussed some of the problems associated with that strategy. These include increasing the risks of drug development, price gouging, fostering a blind-leading-the-blind phenomenon... Read more

Children's Hospital of Philadelphia tops rankings for third year

Tuesday, June 11, 2013, 4:14 PM
For the third consecutive year, Children’s Hospital of Philadelphia has landed in the top spot on U.S. News & World Report’s annual “honor roll” of best pediatric hospitals in the nation. In addition to the overall honor roll ranking, U.S. News evaluates children’s... Read more

Pharma needs an R&D strategy

Thursday, June 6, 2013, 10:08 AM
Recently a knowledgeable pharma veteran lamented the fact that the industry has not widely adopted what he considers a particularly useful approach to drug development. One company "had it right," he wrote, "when their research model was to study particular pathways and find drugs to affect various... Read more
About this blog

Check Up covers major health events in our region and offers everything from personal health advice to an expert look at health reform. Read about some of our bloggers here.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section

Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Also on Philly.com:
Stay Connected